Results for bevacizumab translation from Maltese to English

xelox+ bevacizumab
xelox+ bevacizumab

+ bevacizumab (n=699)
bevacizumab (n=699)

plaċebo jew bevacizumab
placebo or bevacizumab

bevacizumab 25 mg kull ml.
bevacizumab 25 mg per ml.

kull kunjett fih 100 mg bevacizumab
each vial contains 100 mg bevacizumab.

is-sustanza attiva hi bevacizumab.
the active substance is bevacizumab.

huwa fih is- sustanza attiva bevacizumab.
it contains the active substance bevacizumab.

taħlita ta’ bevacizumab u sunitinib malate
combination of bevacizumab and sunitinib malate

pazjenti mingħajr bevacizumab minn qabel (n (%))
patients with no prior bevacizumab (n (%))

vectibix flimkien ma ’ bevacizumab u korsijiet kimoterapewtiċi
vectibix in combination with bevacizumab and chemotherapy regimens

xeliri modifikat + bevacizumab (itt: n= 120)
modified xeliri+ bevacizumab (itt: n= 120)

folfox- 4 + 400 mg/ m2 iv bolus, bevacizumab
400 mg/ m2 iv bolus,

grupp ct+bv (kimoterapija flimkien ma’ bevacizumab):
ct+bv arm (chemotherapy plus bevacizumab):

6 treddigħ mhux magħruf jekk bevacizumab jitneħħix fil- ħalib uman.
lactation it is not known whether bevacizumab is excreted in human milk.

pazjenti bi bevacizumab minn qabel u awżiljarji esklużi biss (n (%))
patients with prior bevacizumab excluding adjuvant only (n (%))

effett ta’ sustanzi antineoplastiċi fuq il-farmakokinetika ta’ bevacizumab
effect of antineoplastic agents on bevacizumab pharmacokinetics

effett ta’ bevacizumab fuq il-farmakokinetika ta’ sustanzi antineoplastiċi oħra
effect of bevacizumab on the pharmacokinetics of other antineoplastic agents

qed tieħu inibituri tal-anġjoġenesi (bħal bevacizumab, jew thalidomide),
you are taking angiogenesis inhibitors (such as bevacizumab, or thalidomide),

avastin fih is- sustanza attiva bevacizumab, li huwa antikorp monoklonali umanizzat.
avastin contains the active substance bevacizumab, which is a humanised monoclonal antibody.

ma sarux studji biex jivvalutaw il-potenzjal mutaġeniku u karċinoġeniku ta’ bevacizumab.
studies to evaluate the mutagenic and carcinogenic potential of bevacizumab have not been performed.